MYCO-007
| Clinical data | |
|---|---|
| Other names | MYCO007 |
| Drug class | Entactogen; Empathogen |
MYCO-007 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.[1][2][3][4][5] It is a short-acting MDMA analogue.[2][4][5] MYCO-007 is being developed by Mydecine.[1] As of February 2024, it is in preclinical research.[1] The chemical structure of MYCO-007 does not yet appear to have been disclosed.[1] 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) were described in Mydecine's patent for short-acting MDMA analogues[6][7][8]
See also
[edit]References
[edit]- ^ a b c d "Delving into the Latest Updates on MYCO-007 with Synapse". synapse.patsnap.com.
- ^ a b "Prospectus Supplement" (PDF). Mydecine Innovations Group Inc. 15 September 2023. Retrieved 23 October 2024.
MYCO - 006 and 007 represent families of molecules that are based on MDMA molecules. MYCO -006 and MYCO – 007 have been developed in order to reduce the overall acute experience time of Generation 1 MDMA by increasing the metabolism properties of the drug.
- ^ Mydecine Innovations Group (19 July 2022). "Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs". GlobeNewswire News Room. Retrieved 23 October 2024.
Mydecine [...] announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been specifically designed by experts at Mydecine to have a shorter half life than traditional MDMA. The Company has named this family of novel molecules MYCO-006 and have applied for patent coverage with the World Intellectual Property Organization.
- ^ a b Borchardt D (17 August 2022). "Psilocybin Company Mydecine Is Down To $300k In Cash". Green Market Report. Retrieved 29 January 2025.
Just last month Mydecine announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs had been specifically designed by experts at Mydecine to have a shorter half-life than traditional MDMA. The company has named this family of novel molecules MYCO-006 and applied for patent coverage with the World Intellectual Property Organization.
- ^ a b Dunne R (24 April 2023). "Mydecine's MDMA with rapid onset and a short duration shows promising results". Mugglehead Investment Magazine. Retrieved 29 January 2025.
The effects from the company's MYCO-006 compounds last for only two hours and set in four times as fast [...] The biotech company announced the results of its preclinical mice studies on Monday examining its proprietary MDMA drug family MYCO-006. [...] MYCO-006 compounds have the same therapeutic effect as standard MDMA but have demonstrated a shorter half-life duration in animal research. The projected duration of the MYCO-006 compounds is around one to two hours, which is approximately one-third the length of the conventional six to eight hours for regular MDMA. Additionally, the onset of MYCO-006 compounds is expected to be four times faster than Gen-1 or regular MDMA. The drugs are intended to treat conditions such as PTSD, chronic pain, depression and addiction.
- ^ US 2024/0197679, Hoyer DW, Roscow RF, Ling R, Gao C, "Novel short-acting psychoactive compounds of the mdma class", published 20 June 2024, assigned to Mydecine Innovations Group Inc.
- ^ "1-(1,3-benzoxathiol-5-yl)-N-methylpropan-2-amine". PubChem. U.S. National Library of Medicine. Retrieved 23 October 2024.
- ^ "1-(1,3-benzoxathiol-5-yl)-N,N-dimethylpropan-2-amine". PubChem. U.S. National Library of Medicine. Retrieved 23 October 2024.
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |